CAJ | 학술논문

大出血是急性冠状动脉综合征患者经皮冠状动脉介入术治疗预后不佳和病死率增加的主要危险因素，并可导致住院时间延长和费用增加。因此，预防出血和治疗缺血同等重要。多项临床研究表明，直接凝血酶抑制剂比伐卢定可减少缺血事件，尤其在出血高危患者，可减少出血风险，现就比伐卢定在急性冠状动脉综合征患者经皮冠状动脉介入术中的应用做一综述。
대출혈시급성관상동맥종합정환자경피관상동맥개입술치료예후불가화병사솔증가적주요위험인소，병가도치주원시간연장화비용증가。인차，예방출혈화치료결혈동등중요。다항림상연구표명，직접응혈매억제제비벌로정가감소결혈사건，우기재출혈고위환자，가감소출혈풍험，현취비벌로정재급성관상동맥종합정환자경피관상동맥개입술중적응용주일종술。
Major bleeding remains a major risk factor for percutaneous coronary intervention of acute coronary syndromes and is asso-ciated with higher morbidity, mortality, prolonged hospital stay and costs.The recognition that bleeding is an important factor in patient out-comes, has meant that the prevention of bleeding has become as an important goal as the prevention of ischemia.The direct thrombin inhibi-tor bivalirudin has been shown to reduce ischemia, and importantly is associated with less bleeding.In this article we review evidence that supports the use of bivalirudin across all spectrums of coronary syndromes and percutaneous coronary intervention.